Haloperidol Crescent Pharma International (Haloperidol)

Haloperidol Crescent Pharma International is indicated for the treatment of several psychiatric disorders where dopamine blockade is therapeutic.

• Management of schizophrenia, including both chronic maintenance and acute exacerbations.
• Treatment of acute psychotic episodes associated with bipolar disorder or major depressive disorder.
• Reduction of motor and vocal tics in patients with Tourette syndrome.
• Control of severe agitation or aggression in inpatient or emergency settings when rapid symptom relief is required.
• Adjunctive use for psychosis secondary to neurological diseases such as Huntington’s disease or Parkinson’s disease medication‑induced psychosis.

The safety profile of haloperidol includes a range of neurological, cardiovascular and metabolic effects that vary in frequency.

Common

• Extrapyramidal symptoms such as tremor, rigidity, and akathisia.
• Drowsiness or sedation.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal discomfort.

Serious

• Tardive dyskinesia, a potentially irreversible movement disorder.
• Neuroleptic malignant syndrome, characterized by fever, muscle rigidity, and autonomic instability.
• QT interval prolongation leading to cardiac arrhythmias.

Clinicians should evaluate patient‑specific factors and monitor for adverse events when prescribing haloperidol.

• Assess cardiovascular risk, especially in patients with known QT prolongation or electrolyte disturbances.
• Use the lowest effective dose and limit duration to reduce risk of tardive dyskinesia.
• Monitor for signs of neuroleptic malignant syndrome, particularly during dose escalation.
• Caution in patients with hepatic or renal impairment, as clearance may be altered.
• Evaluate for potential worsening of Parkinsonian symptoms in individuals with pre‑existing movement disorders.
• Consider pregnancy and lactation status; haloperidol crosses the placenta and is excreted in breast milk.

Haloperidol may interact with several medications that affect its metabolism or cardiac conduction.

Avoid

• Concurrent use with other dopamine antagonists or high‑potency antipsychotics, which can increase extrapyramidal risk.
• Co‑administration with drugs that significantly prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics).
• Strong CYP3A4 inhibitors such as ketoconazole or clarithromycin, which raise haloperidol plasma levels.

Use with caution

• CYP3A4 inducers like carbamazepine or rifampin, which may reduce efficacy.
• CNS depressants including benzodiazepines, opioids, or alcohol, which can enhance sedation.
• Anticholinergic agents, which may mask early signs of extrapyramidal symptoms.